CompletedEarly Phase 1

Novel Energy Metabolic Signaling Molecule With Therapeutic Potential

Finland27 participantsStarted 2019-10-04

Plain-language summary

Altogether a 25-day study. First 4 days non-blinded with water before 0-control blood samples (Day0). Thereafter blinded for 21 days (3 weeks). Study group was apparently healthy 50-60 -year-old males and females (N=27).

Who can participate

Age range50 Years – 60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * healthy 50-60 year-old females and males Exclusion Criteria: * history of cardiovascular diseases, overweight (BMI \>32)

What they're measuring

Acute change in blood IL-6, insulin, and glucose after RH013001 or Placebo dose at Day7

Timeframe: 45 minutes control blood sample

Change in blood metrices from Day1 (0-control / baseline) to Day7

Timeframe: 7 days

Trial details

NCT IDNCT04713319

SponsorPetteri Hirvonen

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2021-12-31

View on ClinicalTrials.gov More Healthy Participants trials